An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome

Trial Profile

An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subject With Fragile X Syndrome

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2015

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions; Registrational
  • Sponsors Seaside Therapeutics
  • Most Recent Events

    • 10 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top